Loading data for ALKS — first visit, this takes a few seconds.

Alkermes plc (ALKS)

NasdaqGS: ALKS · Precio en tiempo real · USD

47.20

+0.21 (0.45%)

Al cierre: Sep 01, 2026, 8:00 PM

47.20

+0.00%

Fuera de horario: 7:30 PM

Alerta

Alert

El precio, las cifras principales y las últimas noticias, en un solo sitio.

No hay datos disponibles

Precio de compra	39.86
Capitalización de mercado	7.92B
Ingresos (TTM)	1.67B
Beneficio neto (TTM)	66.1M
	0.27
	0.38
	124.21
	25.82
P/B (TTM)	4.37
P/S (TTM)	4.75
Fecha de resultados	Oct 28, 2026

Precio de venta	53.36
Volumen	1,191,259
Volumen medio (20D)	1,960,512
Abierto	47.00
Anterior Cerrar	46.99
Rango del día	46.67 - 47.34
Rango de 52 semanas	25.17 - 55.67
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de ALKS

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product cand...

[Leer más]

Industria Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Fecha Jul 16, 1991

Empleados 2,050

Bolsa de Valores NasdaqGS

Símbolo bursátil ALKS

Sitio web https://www.alkermes.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Alkermes plc fueron 1.48B, una disminución de -5.25% en comparación con 1.56B del año anterior. Las ganancias fueron 241.66M, una disminución de -34.16%.

Estados financieros

Sorpresa de resultados

Alkermes plc ha publicado sus resultados trimestrales en Jul 28, 2026:

Ingresos de n/a falla las estimaciones por $0, con -100.00% Disminución interanual.
EPS de 0.7 supera las estimaciones en 0.41, con 2.94% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Alkermes plc publique sus resultados el Oct 28, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Por qué se movió el precio

Noticias

1 semana hace · Zacks

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

1 semana hace · Zacks

Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?

Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.

2 semanas hace · Zacks

ALKS Stock Rises 27% in 3 Months: Here's What You Should Know

Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.

3 semanas hace · Insider Monkey

Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?

It was reported on July 28 that Alkermes plc (NASDAQ:ALKS) sank 5% to $50.05 following its second-quarter 2026 financial report. Despite topping top-line consensus estimates with a 27% year-over-year ...

3 semanas hace · The Wall Street Journal

The Race to Come Up With the Next Big Sleep Drug

The FDA approved the first drug to treat a root cause of narcolepsy, which could help other sleep conditions as well.

Página 1 de 2

Alkermes plc (ALKS)